Evidence map›Paper›PMID 28425052›Full record

ArticleJournal of the American Society for Mass Spectrometry2017

DMSO Assisted Electrospray Ionization for the Detection of Small Peptide Hormones in Urine by Dilute-and-Shoot-Liquid-Chromatography-High Resolution Mass Spectrometry.

Péter Judák, Janelle Grainger, Catrin Goebel, Peter Van Eenoo, Koen Deventer

Abstract readValidation Study
PubMed Publisher
In one paragraph

Article in Journal of the American Society for Mass Spectrometry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. A distributable LC-MS/MS method for the measurement of serum thyroglobulin.Journal of mass spectrometry and advances in the clinical lab · 2022
    Article
  7. Review
  8. Article
  9. Interpol review of toxicology 2016-2019.Forensic science international. Synergy · 2020
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Péter JudákDepartment of Clinical Chemistry, Microbiology and Immunology, Doping Control Laboratory, Ghent University, Technologiepark 30 B, B-9052, Zwijnaarde, Belgium. peter.judak@ugent.be.ORCID 0000-0002-1625-6372
Janelle GraingerAustralian Sports Drug Testing Laboratory, National Measurement Institute, 105 Delhi Road, North Ryde, New South Wales, 2113, Australia.
Catrin GoebelAustralian Sports Drug Testing Laboratory, National Measurement Institute, 105 Delhi Road, North Ryde, New South Wales, 2113, Australia.
Peter Van EenooDepartment of Clinical Chemistry, Microbiology and Immunology, Doping Control Laboratory, Ghent University, Technologiepark 30 B, B-9052, Zwijnaarde, Belgium.
Koen DeventerDepartment of Clinical Chemistry, Microbiology and Immunology, Doping Control Laboratory, Ghent University, Technologiepark 30 B, B-9052, Zwijnaarde, Belgium.
Ghent University · BENational Measurement Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The mobile phase additive (DMSO) has been described as a useful tool to enhance electrospray ionization (ESI) of peptides and proteins. So far, this technique has mainly been used in proteomic/peptide research, and its applicability in a routine clinical laboratory setting (i.e., doping control analysis) has not been described yet. This work provides a simple, easy to implement screening method for the detection of doping relevant small peptides (GHRPs, GnRHs, GHS, and vasopressin-analogues) with molecular weight less than 2 kDa applying DMSO in the mobile phase. The gain in sensitivity was sufficient to inject the urine samples after a 2-fold dilution step omitting a time consuming sample preparation. The employed analytical procedure was validated for the qualitative determination of 36 compounds, including 13 metabolites. The detection limits (LODs) ranged between 50 and 1000 pg/mL and were compliant with the 2 ng/mL minimum detection level required by the World Anti-Doping Agency (WADA) for all the target peptides. To demonstrate the feasibility of the work, urine samples obtained from patients who have been treated with desmopressin or leuprolide and urine samples that have been declared as adverse analytical findings were analyzed. Graphical Abstract ᅟ.

Indexed as

Chromatography, High Pressure LiquidChromatography, LiquidDimethyl SulfoxideDoping in SportsHumansLimit of DetectionPeptide HormonesSpectrometry, Mass, Electrospray IonizationSubstance Abuse DetectionTandem Mass SpectrometryDimethyl SulfoxidePeptide HormonesDilute-and-shootDMSODoping controlHigh-resolution mass spectrometryHRMSPeptidesUrine

Identifiers

PMID28425052
OpenAlexW2606787706

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.